Embecta Corp EMBC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EMBC is a good fit for your portfolio.
News
-
embecta to Report Fiscal Second Quarter 2024 Financial Results
-
embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes
-
Embecta Corp. Reports First Quarter Fiscal 2024 Financial Results
-
embecta Announces Quarterly Cash Dividend
-
embecta to Participate in the 11th Annual BTIG MedTech Conference
Trading Information
- Previous Close Price
- $10.72
- Day Range
- $10.66–10.98
- 52-Week Range
- $9.93–32.00
- Bid/Ask
- $9.00 / $11.00
- Market Cap
- $626.46 Mil
- Volume/Avg
- 357,508 / 440,323
Key Statistics
- Price/Earnings (Normalized)
- 3.45
- Price/Sales
- 0.56
- Dividend Yield (Trailing)
- 5.60%
- Dividend Yield (Forward)
- 5.60%
- Total Yield
- 5.60%
Company Profile
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Value
- Total Number of Employees
- 2,200
- Website
- https://www.embecta.com
Comparables
Valuation
|
Metric
|
EMBC
|
LUNG
|
OM
|
|---|---|---|---|
Price/Earnings (Normalized) | 3.45 | — | — |
Price/Book Value | — | 2.44 | 1.01 |
Price/Sales | 0.56 | 4.15 | 0.94 |
Price/Cash Flow | 5.38 | — | — |
Price/Earnings
EMBC
LUNG
OM
Financial Strength
|
Metric
|
EMBC
|
LUNG
|
OM
|
|---|---|---|---|
Quick Ratio | 1.55 | 5.62 | 4.27 |
Current Ratio | 2.20 | 6.50 | 5.26 |
Interest Coverage | 1.59 | −19.37 | −13.39 |
Quick Ratio
EMBC
LUNG
OM
Profitability
|
Metric
|
EMBC
|
LUNG
|
OM
|
|---|---|---|---|
Return on Assets (Normalized) | 12.52% | −22.61% | −39.03% |
Return on Equity (Normalized) | — | −31.80% | −72.89% |
Return on Invested Capital (Normalized) | 30.00% | −25.75% | −44.98% |
Return on Assets
EMBC
LUNG
OM
Medical Instruments & Supplies Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Tpdkbsnlhr | Bdlm | $133.8 Bil | |
BDX
| Becton Dickinson & Co | Crgbkks | Thzdwf | $67.6 Bil | |
ALC
| Alcon Inc | Qhfhyjcm | Qnvkfl | $39.1 Bil | |
CLPBY
| Coloplast A/S ADR | Wprfdykc | Phtp | $29.4 Bil | |
WST
| West Pharmaceutical Services Inc | Knzrrzcr | Rmrlt | $28.6 Bil | |
RMD
| ResMed Inc | Plgfmtmpm | Xttbxb | $27.1 Bil | |
BAX
| Baxter International Inc | Tlpxrrq | Gjtzpm | $20.9 Bil | |
COO
| The Cooper Companies Inc | Slnltzsn | Mwvzkz | $18.2 Bil | |
HOLX
| Hologic Inc | Nhlwnrkh | Jvbdr | $17.9 Bil | |
TFX
| Teleflex Inc | Nyz | Zhkw | $9.9 Bil |